Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

Claudia G. Liberini,Kieran Koch-Laskowski,Evan Shaulson,Lauren E. McGrath,Rachele K. Lipsky,Rinzin Lhamo,Misgana Ghidewon,Tyler Ling,Lauren M. Stein,Matthew R. Hayes
DOI: https://doi.org/10.1038/s41598-019-44591-8
IF: 4.6
2019-06-11
Scientific Reports
Abstract:A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has highlighted combination therapies as a promising strategy to enhance sustained weight loss. Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therapies produce greater food intake- and body weight-suppressive effects compared to monotherapies in both lean and diet-induced obese (DIO) rats. In chow-maintained rats, systemic amylin and GLP-1 combine to reduce meal size. Furthermore, the amylin and GLP-1 analogs salmon calcitonin (sCT) and liraglutide produce synergistic-like reductions in 24 hours energy intake and body weight. The administration of sCT with liraglutide also led to a significant enhancement in cFos-activation in the dorsal-vagal-complex (DVC) compared to mono-therapy, suggesting an activation of distinct, yet overlapping neural substrates in this critical energy balance hub. In DIO animals, long-term daily administration of this combination therapy, specifically in a stepwise manner, results in reduced energy intake and greater body weight loss over time when compared to chronic mono- and combined-treated groups, without affecting GLP-1 receptor, preproglucagon or amylin-receptor gene expression in the DVC.
multidisciplinary sciences
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore whether the combined application of amylin and glucagon - like peptide - 1 (GLP - 1) can more effectively promote and maintain long - term weight loss, especially in obesity models. Specifically, the researchers hope to verify the following hypotheses: 1. **Effect of combination therapy**: Whether the combined treatment of amylin and GLP - 1 can reduce food intake and weight gain more effectively than single - agent therapy. 2. **Investigation of neural mechanisms**: Whether the combined treatment achieves a more long - lasting weight control effect by activating different but partially overlapping neural circuits. 3. **Effectiveness of step - wise dosing strategy**: Whether the step - wise introduction of amylin and GLP - 1 receptor agonists (such as salmon calcitonin sCT and liraglutide) can break the weight - loss plateau in existing treatment methods, thereby achieving longer - term weight loss. To answer these questions, the researchers conducted multiple experiments, including acute dosing experiments, chronic dosing experiments, and gene expression analysis at the molecular level. These experiments mainly focused on the following aspects: - **Acute dosing experiments**: Evaluate the effects of a single injection of amylin, GLP - 1 and their analogues on food intake and body weight changes in rats on a normal diet. - **Chronic dosing experiments**: Study the effects of long - term use of amylin and GLP - 1 analogues (alone or in combination) on food intake and body weight changes in diet - induced obese (DIO) rats. - **Neural mechanism research**: Observe the activation of neurons in the dorsal vagal complex (DVC) under different treatment conditions through c - Fos immunohistochemical staining. - **Gene expression analysis**: Detect changes in amylin - and GLP - 1 - related gene expression in the DVC after long - term treatment. Finally, the study shows that the combined application of amylin and GLP - 1 analogues, especially using a step - wise dosing strategy, can achieve a more significant and long - lasting weight - loss effect in obese rats without affecting the gene expression of related receptors in the DVC, suggesting that these receptors are still effective drug targets. ### Key formulas and symbol explanations - \( \text{Weight change} = \text{Initial weight}-\text{Final weight} \) - \( \text{Energy intake}=\sum (\text{Daily food intake}) \) These formulas are used to describe key variables measured in the experiment, such as weight change and energy intake.